H.R. 9923 aims to enhance the United States' leadership in biotechnology by recruiting and training experts in the field. These experts would advocate for U.S. biotechnology interests on an international level, ensuring that U.S. priorities are represented in global discussions and negotiations related to biotechnology.
Supporters of H.R. 9923 highlight its potential to strengthen U.S. influence in the rapidly evolving biotechnology sector. They argue that by investing in expert training and international advocacy, the bill could help the U.S. maintain its competitive edge and promote global standards that align with American values and innovations.
Critics of H.R. 9923 express concern that the bill may prioritize U.S. interests at the expense of global cooperation on biotechnology issues. Some argue that it could lead to a unilateral approach that undermines collaborative efforts needed to address global challenges such as health crises and environmental sustainability.
All donations are from employees of Applied Materials, Inc., which may have an interest in biotechnology diplomacy. This concentration of donations suggests a potential medium risk of conflict of interest.
Top industries and organizations funding James (Jim) Moylan, from FEC data.
Source: FEC campaign finance records
